American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease

Gastroenterology. 2013 Dec;145(6):1464-78.e1-5. doi: 10.1053/j.gastro.2013.10.046.
No abstract available

Keywords: 6-MP; 6-mercaptopurine; ACG; ADA; AZA; American College of Gastroenterology; BSG; British Society of Gastroenterology; CD; CDAI; CI; CZP; Crohn's Disease Activity Index; Crohn's disease; ECCO; European Crohn's and Colitis Organisation; GRADE; Grading of Recommendations Assessment, Development and Evaluation; HR; IBD; IFX; MTX; OR; PICO; RCT; RR; SIR; TNF; adalimumab; azathioprine; certolizumab pegol; confidence interval; hazard ratio; inflammatory bowel disease; infliximab; methotrexate; odds ratio; population, intervention, comparator, and outcome; randomized controlled trial; relative risk; standardized incidence ratio; tumor necrosis factor.

Publication types

  • Review

MeSH terms

  • Azathioprine / therapeutic use*
  • Crohn Disease / drug therapy*
  • Gastroenterology
  • Humans
  • Mercaptopurine / therapeutic use*
  • Methotrexate / therapeutic use*
  • Remission Induction
  • Societies, Medical
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • United States


  • Tumor Necrosis Factor-alpha
  • Mercaptopurine
  • Azathioprine
  • Methotrexate